2Griffin J H, Fernandez J A, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis [ J ]. Thromb Haemost ,2001,86 ( 1 ) : 386-394.
3Heywood D M, Carter A M, Catto A J, et al. Polymorphism of the factor Ⅶ gene and circulating FⅦ :C levels in relation to acute cerebrovascular disease and poststroke mortality [ J ]. Stroke, 1997,28(4):816-821.
4Heinrich J, Balleisen L,Schulte H,et al. Fibrinogen and factor Ⅶ in the prediction of coronary risk: results from the PROCAM study in healthy men[ J]. Arterioscler Thromb, 1994,14:54-59.
5Tu Z,Kelley V R,Collins T,et al. I kappa B kinase is critical for TNF-alpha-induced VCAM1 gene expression in renal tubular epithelial cells [ J]. J Immunol,2001,166 ( 11 ) :6839-6846.
6Willam C, Schindler R, Frei U, et al. Increases in oxygen tension stimulate expression of ICAM-1 and VCAM-1 on human endothelial cells [ J ]. Am J Physiol, 1999,276 ( 6 Pt 2 ) : H2044-2052.
7Bajzar L, Manuel R, Nesheim M E. Purification and characterization of TAFI,a thrombin activatable fibrinolysis inhibitor [ J ]. J Bio Chem, 1995,270(24) : 14477-14484.
8Wang W, Boffa M B, Bajzar L, et al. A study of the mechanism of inhibition of fibfinolysis by activated thrombin activable fibrinolysis inhibitor[ J]. Biol Chem, 1998,273 (42) :27176-27181.
9Hori Y, Gabazza E C, Yano Y,et al. Insulin resistance is associated with increased circulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients [J]. J Clin Endocrinol Metab.2002.87(2) :660-665.
10Gaede P,Vedel P, Parring H H, et al. Elevated levels of plasma von Willebrand factor and the risk of macro-and micro-vascular disease in type 2 diabetic patients with microalbuminuria [ J ]. Nephrol Dial Transplant, 2001,16 ( 10 ) : 2028-2033.
